The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The only recent RNS I have seen re holdings was Berkeley Energia selling around 2%. If they anything like other Spanish companies at the mo they needed to raise money. No idea if Peel Hunt selling, but Anglo have bought a lot of shares over the last weeks, and still have 3 weeks to complete. Its really not important.
Mkts are forward looking...obviously there are doubts as to where the world economy will be in 6 months time. With a stronger second wave, and maybe even a third wave things could get very ugly if there is no vaccine. Cant see a real strong move to the upside without a vaccine, and then we will have to see what sort of recovery / pick up there is.
The mkts are extremely nervous...upside in any stock (apart from biotechs) is v limited at the moment. I personally can´t see any major reason for stocks to go better until there is a vaccine out. The situation is likely to get worse before it gets better. One has to look for value in stocks with sound fundamentals that have been really hammered, and if you decide to go long then you just need to wait until this is over.
There was a big seller around until a few days ago, but he appears to be finished. They have plenty of time between now and 25th November to complete.
It may be that the large seller who was around has now finished, so they are now just sitting on the bid and mopping up any sellers that come along.
This is the Abstract from the Asco 2020 Annual Meeting....Background:
MCY-M11 is a mesothelin-targeting chimeric antigen receptor (CAR) therapy made by a non-viral, mRNA-based platform, for rapid ( < 1 day) CAR manufacturing. We are conducting a phase I dose escalation trial in ovarian cancer and malignant peritoneal mesothelioma (MPM) (NCT03608618).
Methods:
MCY-M11 are fresh, non-expanded, autologous peripheral blood mononuclear cells (PBMCs) transfected by flow electroporation with mRNA encoding a human anti-mesothelin CAR. Following a 3+3 design, patients are treated in dose level (DL) escalating cohorts (DL1 1.0 x 107, DL2 5.0 x 107, DL3 1.0 x 108, DL4 5.0 x 108 cells/dose), in one cycle of weekly x 3 doses, intraperitoneal (ip) without preconditioning chemotherapy.
Results:
By January 2020, CP-M11-101 study successfully completed DL1 and DL2 without safety concerns. Based on 11 patients treated in DL1, DL2 and DL3, ip infusion of MCY-M11 is safe and well tolerated. No infusion-related adverse events and no dose limiting toxicities (DLTs) have occurred. No neurotoxicity has been observed. Most reported treatment-related adverse events have been Grades 1-2 per NCI CTCAE. One patient in DL3 presented with G2 pericarditis, fever and transient neutropenia clinically assessed as related SAEs, that resolved without further complications. These events were assessed as on-target off-tumor effects and possibly G1 cytokine release syndrome (CRS). Two unrelated SAEs (G2 confusion in a patient in DL2; G3 enterocutaneous fistula in a patient in DL3) were reported. These 2 patients have been replaced as they did not complete the evaluation period (3 weekly infusions and the DLT 43 day follow up). There have been no treatment-related discontinuations or deaths. Three patients in DL2 showed stable disease (SD) by RECIST 1.1 at the end of the DLT period. Of them, 1 completed the study and did not participate in additional follow up, 1 remained in SD 6 months, and 1 remained in SD 2 months. In DL3, 1 patient remains in SD at 2 months, and evaluation is pending for the other 2 patients. Enrollment is ongoing.
Conclusions:
Feasibility of 1-day manufacturing of MCY-M11 for ip delivery is demonstrated. Treatment has been safe. Initial SD observed in DL2 and DL3 with one-cycle infusions is encouraging and supports exploration of additional strategies such as the addition of preconditioning chemotherapy and multiple cycles to increase efficacy. Clinical trial information: NCT03608618.